Editas Medicine Inc (EDIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Editas Medicine Inc (EDIT) has a cash flow conversion efficiency ratio of -5.232x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.06 Million) by net assets ($4.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Editas Medicine Inc to measure how much of total assets are equity-financed.
Editas Medicine Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Editas Medicine Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Editas Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Editas Medicine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southeast Cement Co Ltd
TW:1110
|
0.067x |
|
Globus Spirits Limited
NSE:GLOBUSSPR
|
0.246x |
|
Suprema Inc
KQ:236200
|
0.047x |
|
Blackrock Silver Corp
V:BRC
|
-0.106x |
|
K-Fast Holding AB (publ)
ST:KFAST-B
|
0.004x |
|
Sportking India Limited
NSE:SPORTKING
|
0.142x |
|
Keyfield International Berhad
KLSE:5321
|
0.117x |
|
XinJiang GuoTong Pipeline Co Ltd
SHE:002205
|
-0.121x |
Annual Cash Flow Conversion Efficiency for Editas Medicine Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Editas Medicine Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see EDIT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.29 Million | $-165.24 Million | -6.055x | -286.66% |
| 2024-12-31 | $134.27 Million | $-210.28 Million | -1.566x | -313.62% |
| 2023-12-31 | $349.10 Million | $-132.18 Million | -0.379x | +23.00% |
| 2022-12-31 | $360.68 Million | $-177.35 Million | -0.492x | -66.19% |
| 2021-12-31 | $553.64 Million | $-163.80 Million | -0.296x | +35.25% |
| 2020-12-31 | $393.59 Million | $-179.84 Million | -0.457x | -194.86% |
| 2019-12-31 | $262.44 Million | $-40.67 Million | -0.155x | +19.93% |
| 2018-12-31 | $236.16 Million | $-45.71 Million | -0.194x | -327.65% |
| 2017-12-31 | $208.08 Million | $-9.42 Million | -0.045x | +87.80% |
| 2016-12-31 | $134.61 Million | $-49.93 Million | -0.371x | -670.56% |
| 2015-12-31 | $-83.11 Million | $-5.40 Million | 0.065x | -88.51% |
| 2014-12-31 | $-15.29 Million | $-8.65 Million | 0.566x | -64.16% |
| 2013-12-31 | $-1.76 Million | $-2.78 Million | 1.579x | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more